Diag2Tec

Diag2Tec is a private French preclinical CRO focused on hematological malignancies, with particular depth in multiple myeloma as well as lymphoma and leukemia. The company provides in vitro and ex vivo drug testing, immunotherapy assay support, biomarker discovery, bioinformatics, and genomic profiling services to biotech, pharmaceutical, CRO, and academic clients. Its offering is built around proprietary disease models, a collection of human myeloma cell lines, access to primary patient-derived samples, and associated multi-omics and clinical datasets. Diag2Tec positions itself as a precision medicine-enabling research partner that helps clients evaluate efficacy, study mechanisms of action and resistance, and identify predictive and prognostic biomarkers in blood cancers.